NDAC Calls For Predefined Endpoints In Consumer Behavior Trials
This article was originally published in The Tan Sheet
Executive Summary
Rx-to-OTC switch sponsors will be expected to work with FDA to establish predefined endpoints for each consumer behavior trial they plan, if the agency follows advice given by the Nonprescription Drugs Advisory Committee during a Sept. 25 meeting
You may also be interested in...
Draft Label Comprehension Study Guidance Stresses Quality And Quantity
FDA wants sponsors conducting label comprehension studies to take into account subjects' thought processes - reflected in their verbatim answers to test questions
Draft Label Comprehension Study Guidance Stresses Quality And Quantity
FDA wants sponsors conducting label comprehension studies to take into account subjects' thought processes - reflected in their verbatim answers to test questions
Draft Label Comprehension Study Guidance Stresses Quality And Quantity
FDA wants sponsors conducting label comprehension studies to take into account subjects' thought processes - reflected in their verbatim answers to test questions